CO6910185A2 - Enonas tricíclicas y pirimidinil como antioxidantes modulares de la inflamación - Google Patents

Enonas tricíclicas y pirimidinil como antioxidantes modulares de la inflamación

Info

Publication number
CO6910185A2
CO6910185A2 CO13167243A CO13167243A CO6910185A2 CO 6910185 A2 CO6910185 A2 CO 6910185A2 CO 13167243 A CO13167243 A CO 13167243A CO 13167243 A CO13167243 A CO 13167243A CO 6910185 A2 CO6910185 A2 CO 6910185A2
Authority
CO
Colombia
Prior art keywords
dwarfs
tricyclic
pyrimidinyl
inflammation
antioxidants
Prior art date
Application number
CO13167243A
Other languages
English (en)
Spanish (es)
Inventor
Eric Anderson
Gary Louis Bolton
Bradley CAPRATHE
Xin Jiang
Chitase Lee
William Howard Roark
Melean Visnick
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CO6910185A2 publication Critical patent/CO6910185A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO13167243A 2010-12-17 2013-07-15 Enonas tricíclicas y pirimidinil como antioxidantes modulares de la inflamación CO6910185A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424601P 2010-12-17 2010-12-17

Publications (1)

Publication Number Publication Date
CO6910185A2 true CO6910185A2 (es) 2014-03-31

Family

ID=45470714

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13167243A CO6910185A2 (es) 2010-12-17 2013-07-15 Enonas tricíclicas y pirimidinil como antioxidantes modulares de la inflamación

Country Status (32)

Country Link
US (6) US8513436B2 (enExample)
EP (1) EP2651902B1 (enExample)
JP (1) JP5857068B2 (enExample)
KR (1) KR102000301B1 (enExample)
CN (1) CN103596929B (enExample)
AR (1) AR084353A1 (enExample)
AU (1) AU2011343466B2 (enExample)
BR (1) BR112013015241B1 (enExample)
CA (1) CA2822071C (enExample)
CL (1) CL2013001754A1 (enExample)
CO (1) CO6910185A2 (enExample)
CY (1) CY1120032T1 (enExample)
DK (1) DK2651902T3 (enExample)
EA (1) EA025568B1 (enExample)
ES (1) ES2653717T3 (enExample)
HR (1) HRP20171859T1 (enExample)
HU (1) HUE038046T2 (enExample)
IL (1) IL226923A (enExample)
LT (1) LT2651902T (enExample)
ME (1) ME02973B (enExample)
MX (1) MX2013006902A (enExample)
NO (1) NO2651902T3 (enExample)
NZ (1) NZ612788A (enExample)
PL (1) PL2651902T3 (enExample)
PT (1) PT2651902T (enExample)
RS (1) RS56795B1 (enExample)
SG (1) SG191181A1 (enExample)
SI (1) SI2651902T1 (enExample)
SM (1) SMT201800069T1 (enExample)
TW (1) TWI527788B (enExample)
WO (1) WO2012083306A2 (enExample)
ZA (1) ZA201305060B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043175T2 (hu) 2008-01-11 2019-08-28 Reata Pharmaceuticals Inc Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
PH12013501254A1 (en) 2010-12-17 2016-07-29 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HRP20171859T1 (hr) 2010-12-17 2018-01-26 Reata Pharmaceuticals, Inc. Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
DK3444261T3 (da) 2012-04-27 2021-03-08 Reata Pharmaceuticals Inc 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
MX372772B (es) * 2014-01-24 2020-06-29 Reata Pharmaceuticals Inc Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes.
US11059792B2 (en) 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
US11286226B2 (en) 2017-09-21 2022-03-29 Northwestern University Polycyclic carbogenic molecules and uses thereof as anti-cancer agents
WO2019104030A1 (en) * 2017-11-21 2019-05-31 Biogen Ma Inc. Tetrahydronaphthalene derivatives useful as nrf2 activators
CN112654610B (zh) * 2018-06-15 2024-12-24 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CN114945561A (zh) 2020-01-13 2022-08-26 阿普塔生物治疗公司 新吡唑衍生物
US20250025465A1 (en) * 2021-11-17 2025-01-23 Northwestern University Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma
CN121358860A (zh) * 2023-06-16 2026-01-16 南京科捷基因技术有限公司 肿瘤特异性表达盒及其用途

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875201A (en) 1957-08-28 1959-02-24 Searle & Co Dehydrotigogenone intermediates
US3071577A (en) * 1959-08-13 1963-01-01 Syntex Corp Pyrimidinyl androstanes
US3994935A (en) 1975-11-24 1976-11-30 E. R. Squibb & Sons, Inc. Steroidal 16β-alkyl[16α,17-b]naphthalenes
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
CN1013672B (zh) * 1983-10-03 1991-08-28 美国辉瑞有限公司 2-氨基-5-羟基-4-甲基嘧啶衍生物的制备方法
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
JPH08208479A (ja) * 1994-04-29 1996-08-13 Takeda Chem Ind Ltd クラビンアルカロイド誘導体を含有する鎮痛剤
WO1995029912A1 (en) 1994-04-29 1995-11-09 Takeda Chemical Industries, Ltd. Ergoline derivatives as analgesics
DE69535305T2 (de) * 1994-09-09 2007-06-21 Koyama, Shozo, Matsumoto Mittel zum herabsetzen von molekülfunktionen
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6365768B1 (en) 1999-05-14 2002-04-02 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factors-α modulators, syntheses of said modulators and methods of using modulators
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7087599B2 (en) 2000-02-14 2006-08-08 Merck & Co., Inc. Estrogen receptor modulators
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
JP2004509972A (ja) 2000-09-29 2004-04-02 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 酵母に対する殺真菌活性を有するトリテルペン
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
EP1395255A4 (en) 2000-11-28 2007-09-12 Univ Texas CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF
ES2294047T3 (es) * 2000-12-28 2008-04-01 Ono Pharmaceutical Co., Ltd. Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf.
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
CA2456150A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
WO2003024935A2 (en) 2001-09-19 2003-03-27 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
MXPA04006953A (es) 2002-01-18 2005-06-20 Univ Minnesota Sales cuaternarias de triperpeno como surfactantes biologicamente activos.
JP2005534286A (ja) 2002-03-21 2005-11-17 サネシス ファーマシューティカルズ, インコーポレイテッド キナーゼインヒビターの同定
AU2003303128A1 (en) 2002-05-13 2004-08-13 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
CN1845750B (zh) 2003-09-02 2014-05-07 尤尼根公司 用于预防及治疗认知衰退和年龄相关的记忆障碍的无取代b环类黄酮和黄烷混合物的组合物
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
CA2579231C (en) 2004-09-07 2018-07-10 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2006089406A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
US7902196B2 (en) 2005-03-17 2011-03-08 President And Fellows Of Harvard College Synthesis of avrainvillamide, strephacidin B, and analogues thereof
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
US20070232577A1 (en) 2006-03-23 2007-10-04 Advanced Life Sciences, Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
EP2032594B1 (en) 2006-06-27 2015-09-23 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
WO2008016095A1 (en) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
DK2653873T3 (da) 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
HUE043175T2 (hu) 2008-01-11 2019-08-28 Reata Pharmaceuticals Inc Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. C-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
MX339476B (es) * 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
WO2009134726A1 (en) 2008-04-28 2009-11-05 Abbott Laboratories Substituted pyrimidine derivatives as histamine h4 receptor ligands
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
SMT202000086T1 (it) 2010-04-12 2020-03-13 Reata Pharmaceuticals Inc Bardoxolone metile per il trattamento dell'obesità
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
HRP20171859T1 (hr) 2010-12-17 2018-01-26 Reata Pharmaceuticals, Inc. Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
MX2013006936A (es) 2010-12-17 2013-07-22 Du Pont Ambas azociclicas fungicidas.
JP6001560B2 (ja) 2011-01-31 2016-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−17およびc−3修飾トリテルペノイド
CA2829618C (en) 2011-03-11 2019-07-09 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
DK3444261T3 (da) 2012-04-27 2021-03-08 Reata Pharmaceuticals Inc 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
HRP20171565T1 (hr) 2012-09-10 2017-12-15 Reata Pharmaceuticals, Inc. C17-heteroaril derivati oleanolne kiseline i postupci njihove uporabe
NZ774222A (en) 2013-08-23 2023-01-27 Reata Pharmaceuticals Holdings Llc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
US11192852B2 (en) 2021-12-07
HUE038046T2 (hu) 2018-09-28
RS56795B1 (sr) 2018-04-30
US8513436B2 (en) 2013-08-20
US9884809B2 (en) 2018-02-06
US20180265455A1 (en) 2018-09-20
PT2651902T (pt) 2018-02-01
US20120196880A1 (en) 2012-08-02
US20220281807A1 (en) 2022-09-08
SI2651902T1 (en) 2018-02-28
ES2653717T3 (es) 2018-02-08
KR102000301B1 (ko) 2019-07-15
JP2014501250A (ja) 2014-01-20
SMT201800069T1 (it) 2018-03-08
KR20130130784A (ko) 2013-12-02
HK1189595A1 (zh) 2014-06-13
CA2822071A1 (en) 2012-06-21
TWI527788B (zh) 2016-04-01
CN103596929A (zh) 2014-02-19
AU2011343466A1 (en) 2013-07-25
AR084353A1 (es) 2013-05-08
ME02973B (me) 2018-07-20
CY1120032T1 (el) 2018-12-12
WO2012083306A3 (en) 2012-10-11
MX2013006902A (es) 2013-10-17
EA201390894A1 (ru) 2013-12-30
EP2651902A2 (en) 2013-10-23
LT2651902T (lt) 2018-01-10
US11814338B2 (en) 2023-11-14
JP5857068B2 (ja) 2016-02-10
EA025568B1 (ru) 2017-01-30
US20140051739A1 (en) 2014-02-20
BR112013015241A2 (pt) 2021-04-20
IL226923A (en) 2016-06-30
BR112013015241B1 (pt) 2022-03-29
CA2822071C (en) 2019-07-16
US20160130220A1 (en) 2016-05-12
EP2651902B1 (en) 2017-11-08
DK2651902T3 (en) 2018-01-08
CL2013001754A1 (es) 2013-11-29
SG191181A1 (en) 2013-07-31
US9174941B2 (en) 2015-11-03
WO2012083306A2 (en) 2012-06-21
TW201249785A (en) 2012-12-16
NZ612788A (en) 2015-10-30
HRP20171859T1 (hr) 2018-01-26
CN103596929B (zh) 2016-10-19
PL2651902T3 (pl) 2018-04-30
NO2651902T3 (enExample) 2018-04-07
US20200207706A1 (en) 2020-07-02
AU2011343466B2 (en) 2017-01-05
ZA201305060B (en) 2016-07-27

Similar Documents

Publication Publication Date Title
ME02973B (me) Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
IL223725B (en) Formulations of rifaximin and uses thereof
BR112013011520A2 (pt) pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
BR112014009531A2 (pt) aza-heterociclos bicíclos substituídos como modulares de sirtuína
EP2622818A4 (en) EXPANSION OF ATTENTION COMMANDS
PL2606120T4 (pl) Ludzkie komórki ułatwiające tolerancję i ich zastosowanie
IL215678A0 (en) Modulation of inflammatory responses by factor xi
EP2818149A4 (en) WHEELCHAIR AND BED INCLUDING
SI2528602T2 (sl) Formulacije bendamustina
BR112013012129A2 (pt) composições de adesivos e seus usos
EP2549986A4 (en) MACROPHONE LEAVE TO MULTIPLE OBJECTIVES
HUE042251T2 (hu) Két szikkasztótest elrendezése
PT2616447E (pt) Derivados de pirazina como bloqueadores de enac
BRPI1011784A2 (pt) compostos bicíclicos e tricíclicos como inibidores de kat ii
EP2920299A4 (en) DIFFERENTIATION OF HUMAN FIBROBLASTING CELLS
CU24139B1 (es) Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol
EP2826923A4 (en) WATERLESS URINAL
FR2977381B1 (fr) Dephaseur et repartiteur de puissance
EP2755309A4 (en) POWER FACTOR CORRECTION AND POWER SWITCHING
EP2940781A4 (en) LOADED BODY AND PHOTOELECTRIC CONVERSION ELEMENT
BR112013011974A2 (pt) porca autotravante
EP2821712A4 (en) LIME PROTECTION COLLECTORS WITH MODULAR STRUCTURE
GB2508089B (en) Underpants
PT2580226T (pt) Derivados de trissacárido e sua utilização como adjuvantes
PL2561464T3 (pl) Klasyfikacja profili zakresów

Legal Events

Date Code Title Description
FG Application granted